{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:29:09Z","timestamp":1793507349619,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":1096,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jpainsymman.2023.06.022","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T15:53:28Z","timestamp":1687190008000},"page":"e638-e643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Should Buprenorphine Be Considered a First-Line Opioid for the Treatment of Moderate to Severe Cancer Pain?"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4036-8232","authenticated-orcid":false,"given":"Marcin","family":"Chwistek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0283-858X","authenticated-orcid":false,"given":"Leigh","family":"Kinczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7903-3993","authenticated-orcid":false,"given":"Mellar","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0001","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis","volume":"51","author":"van den Beuken-van Everdingen","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0002","article-title":"Opioids for cancer pain - An overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0003","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/pm\/pnz356","article-title":"Understanding buprenorphine for use in chronic pain: Expert opinion","volume":"21","author":"Webster","year":"2020","journal-title":"Pain Medicine"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0004","article-title":"Buprenorphine for treating cancer pain","volume":"2015","author":"Schmidt-Hansen","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jpainsymman.2023.06.022_bib0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain","volume":"10","author":"Davis","year":"2012","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0006","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamaoncol.2022.2191","article-title":"Consensus-based guidance on opioid management in individuals with advanced cancer-related pain and opioid misuse or use disorder","volume":"8","author":"Fitzgerald Jones","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0007","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","volume":"8","author":"Pergolizzi","year":"2008","journal-title":"Pain Pract"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2605.2007.00824.x","article-title":"Hypogonadism in men receiving methadone and buprenorphine maintenance treatment","volume":"32","author":"Hallinan","year":"2009","journal-title":"Int J Androl"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0009","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00101-003-0506-y","article-title":"Opioids and immunosuppression. Clinical relevance? [in German]","volume":"52","author":"Welters","year":"2003","journal-title":"Anaesthesist"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1185\/03007995.2012.678938","article-title":"Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain","volume":"28","author":"Wolff","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0011","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2741\/2147","article-title":"Buprenorphine in long-term control of chronic pain in cancer patients","volume":"12","author":"Pace","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0012","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/annonc\/mdw097","article-title":"Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \u201creal life\u201d trial on the variability of response to opioids","volume":"27","author":"Corli","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0013","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/j.pain.0000000000002462","article-title":"Effects of opioid rotation to buprenorphine\/naloxone on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder","volume":"163","author":"Veldman","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0014","article-title":"Top ten tips palliative care clinicians should know about buprenorphine","author":"Neale","year":"2022","journal-title":"J Palliat Med"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0015","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2016.38","article-title":"Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors","volume":"41","author":"Falcon","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0016","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1185\/030079905X53315","article-title":"Transdermal buprenorphine in clinical practice: A post-marketing surveillance study in 13,179 patients","volume":"21","author":"Griessinger","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0017","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/15360288.2021.1920547","article-title":"Transdermal buprenorphine use for pain management in palliative care","volume":"35","author":"Hirsch","year":"2022","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0018","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5055\/jom.2014.0197","article-title":"Transdermal opioids for cancer pain control in patients with renal impairment","volume":"10","author":"Melilli","year":"2014","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0019","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpainsymman.2007.09.011","article-title":"Efficacy and safety of transdermal buprenorphine: A randomized, placebo-controlled trial in 289 patients with severe cancer pain","volume":"36","author":"Poulain","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/jocn.16303","article-title":"Transdermal buprenorphine improves overall quality of life and symptom severity in cancer patients with pain","volume":"32","author":"Shen","year":"2023","journal-title":"J Clin Nurs"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0021","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/bja\/aei145","article-title":"Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats","volume":"94","author":"Dahan","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0022","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0023","series-title":"Buprenorphine for chronic pain","year":"2021"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0024","doi-asserted-by":"crossref","first-page":"388","DOI":"10.7326\/M22-2917","article-title":"The use of opioids in the management of chronic pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline","volume":"176","author":"Sandbrink","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1213\/ANE.0000000000002718","article-title":"Treatment of chronic pain with various buprenorphine formulations: A Systematic Review of Clinical Studies","volume":"127","author":"Aiyer","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24152","article-title":"Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: A Systematic Review","volume":"4","author":"Powell","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0027","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/dta.3347","article-title":"Investigation of buprenorphine-related deaths using urinary metabolite concentrations","volume":"14","author":"Mariottini","year":"2022","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0028","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bja.2017.11.086","article-title":"Efficacy and adverse effects of buprenorphine in acute pain management: Systematic review and meta-analysis of randomised controlled trials","volume":"120","author":"White","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC Clinical practice guideline for prescribing opioids for pain - United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41581-021-00484-6","article-title":"Opioids for chronic pain management in patients with dialysis-dependent kidney failure","volume":"18","author":"Tobin","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0031","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/pm\/pnz165","article-title":"Transdermal buprenorphine for controlling pain in patients with critical lower-limb ischemia","volume":"21","author":"Blanco-Antona","year":"2020","journal-title":"Pain Med"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0032","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsxm.2017.12.004","article-title":"Plasma testosterone and sexual function in Southeast Asian men receiving methadone and buprenorphine maintenance treatment","volume":"15","author":"Yee","year":"2018","journal-title":"J Sex Med"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0033","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bph.14105","article-title":"Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: Link to clinical reports of serotonin syndrome","volume":"175","author":"Rickli","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0034","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/j.pain.0000000000002473","article-title":"Declines and regional variation in opioid distribution by U.S. hospitals","volume":"163","author":"Eidbo","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0035","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1742-7843.2010.00649.x","article-title":"Pharmacokinetic\/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models","volume":"108","author":"Andresen","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jpainsymman.2023.06.022_bib0036","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/phar.2676","article-title":"Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review","volume":"42","author":"Spreen","year":"2022","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392423005663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392423005663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:57:06Z","timestamp":1793505426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392423005663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0885392423005663"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2023.06.022","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should Buprenorphine Be Considered a First-Line Opioid for the Treatment of Moderate to Severe Cancer Pain?","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2023.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}